K 053616

WAR 1 4 2006

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

SYNERON MEDICAL Ltd. Polaris WR / ST Applicator

This summary of safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR 807.92.

Submitter:

Syneron Medical Ltd., Tavor Bld.,

Industrial Zone

Yokneam Illit, Israel

Tel. +972.4.909-6200, Fax +972.4. 909-6202

Name of the Device: Polaris WR, ST Applicator

Predicate Devices: This is a Special 510(k) for the Polaris WR that was cleared

under K031671.

Device Description: The Polaris WR is a device that is used for non invasive wrinkle treatment. The Polaris WR treatment is based on the principle of selective (electromagnetic) thermolysis. According to this principle, parameters of optical and RF energy (spectrum, exposure duration and energy density) are chosen and optimized to selectively heat the skin without damaging the epidermis layer.

The Polaris WR is intended for non invasive wrinkle treatment.

The modifications to the Polaris WR, ST applicator do not affect the intended use or alter the fundamental scientific technology of the device. The only device modification is changing the output wavelengths spectrum from 780-980 nm in the original Polaris WR to 700 - 2000 nm on the new Polaris WR, ST applicator.

There are no labeling changes that affect the intended use of the device. The device modifications raise no new issues of safety or effectiveness.

Huir Walden

December 22 2005

Dr. Amir Waldman

VP regulatory & clinical affairs

Syneron Medical Ltd.





MAR 1 4 2006

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Syneron Medical LTD c/o Dr. Amir Waldman VP, Regulatory Affairs Sultam Industrial Park P.O. Box 550 Yokneam Elite 20692, Israel

Re: K053616

Trade/Device Name: Polaris WR, ST Applicator

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery and in

dermatology

Regulatory Class: II

Product Code: GEX, GEI Dated: February 23, 2006 Received: February 24, 2006

Dear Dr. Waldman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,


Mark N. Melkerson

Acting Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure



Sultam Industrial Park P.O.B. 550 Yokneam Elite 20692, Israel Tel: (972) 4 9096200

Fax: (972) 4 9096200

Medical Ltd.

510(k) Number	(if	known)	<u>K053616.</u>
---------------	-----	--------	-----------------

Device Name Polaris WR, ST applicator.

Indications For Use:

The Polaris WR, ST applicator is indicated for non invasive wrinkles treatment.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

OR

Over The Counter Use____

(Optional Format 1-2-96)

(Division Sign-Off)

Division of General, Restorative, and Neurological Devices

510(k) Number ko53616